1

HUMAN HEALTH • ENVIRONMENTAL HEALTH

PerkinElmer, Inc.

Karen Madden, Ph.D.

President

Informatics: Helping our Customers Answer Critical Questions

2

Safe Harbor Statement

• This document shows current intentions regarding product features, behavior,

schedules and support; these intentions may change without notice as we respond to customer requirements.

• Any unreleased products, services or features referenced herein are not currently

available and may not be delivered on time or at all. Customers who purchase

PerkinElmer informatics applications should make their purchase decisions based

upon products, features, and services that are currently available.

3

Improving the health and safety of people and the environment

Environmental Health Human Health

$2.4

BILLION

IN SALES

20%

EBITDA

8,000

EMPLOYEES

4

IMPROVING THE HEALTH AND SAFETY

OF PEOPLE AND THE ENVIRONMENT

2016 STRATEGIC PRIORITIES

DRIVING INNOVATION FOCUSING ON

CUSTOMERS

OPERATIONAL

EFFECTIVENESS

O U R M I S S I O N __________

5

● Is the water clean?

● Is my food safe?

● How healthy is the air I breathe?

● Is my baby healthy?

● Is the blood supply safe?

● Are drug candidates showing efficacy?

Environmental Health Human Health

At PerkinElmer We Provide Answers

6

DETECTION IMAGING INFORMATICS SERVICE

Our Capabilities

7

75% Of revenue

From Products with

Market Position

Top 3

Strong portfolio with

leading positions FOCUSED ON CATEGORY

LEADERSHIP

8

SOLVING CUSTOMER NEEDS

H E A L T H I E R B A B I E S

worldwide to date for a variety

of life-threatening diseases

Our newborn screening

technologies have

450M BABIES

H E L P E D S C R E E N

9

SOLVING CUSTOMER NEEDS

2.25B

reducing the risk of contaminants

Last year, our detection solutions are

used to analyze approximately

AIR, WATER & SOIL

SAMPLES,

A C L E A N E R A N D S A F E R E N V I R O N M E N T

10

SOLVING CUSTOMER NEEDS

Our technologies and

expertise were instrumental

in the development of...

M O R E E F F E C T I V E M E D I C I N E S

22 DRUGS

of the

NEWEST THERAPUTIC

11

Pharma R&D Reality…

R&D activity and spend

increasing

NME Approvals

decreasing

The estimated average pre-tax industry cost per new prescription drug approval (inclusive of failures

and capital costs) is: $2,558M

12

Moore’s Law

What’s going on?

13

Eroom’s Law

• The ‘Better than the Beatles’ problem, which is our tendency to compete against our greatest hits of the past. Consider for example, how hard it would be to come up with a successful pop song if any new song had to be better than the Beatles. How difficult it would be to create a successor candidate for a successful drug like Lipitor? We are tackling harder problems….

• The ‘Cautious Regulator’ problem is the progressive lowering of risk tolerance that raises the bar on safety for new drugs, which makes R&D both costlier and harder.

• The ‘Throw money at it’ tendency is the tendency to just keep pouring more money and resources into a research project or widely held theory until something sticks. It is like throwing good money after bad.

• The ‘Basic Research-Brute Force’ bias, which is the tendency to overestimate the probability that advances in basic research and large scale screening processes will show a molecule safe and effective in clinical trials.

Personalized Medicine

More Data, Evidence

& Monitoring

Faster Insight to Action

Translational Research

Diagnosing the decline in pharmaceutical R&D efficiency Jack W. Scannell, Alex Blanckley, Helen Boldon & Brian Warrington

Nature Reviews Drug Discovery 11, 191-200 (March 2012)

14

Dementia

40M+; set to triple by 2050

Treating and caring

for people with

dementia currently

costs the world more

than US$ 604 billion

per year

Diabetes

400M+ compared to 100M in 1980

Can lead to heart

attack, stroke,

kidney failure, leg

amputation, vision

loss and nerve

damage

Infectious Disease

58 countries and territories reporting

Increase in Guillain-

Barré syndrome as

well as an increase in

babies born with

microcephaly

Cancer

14M+ new cases; 8M deaths WW

Declared War on

Cancer 30 years ago

and now again a

call to action

Science and Research is hard!

15

Big Questions & Answers Requires Big Data

Genomics

● 3 Billion bases per human genome

● 25,000 genes, millions of variants

● Up to 1TB of data per sample

● 1000, 100,000, Million Genome project

● High Volume and Velocity

Imaging

● Millions of compounds / Functional Screening

● Thousands of cells per well,

● Billions of measurements per run

● High degree of automation

● Extremely high Volume and Velocity

Outcomes

● 200,000 registered clinical trials

● Millions of patients, doctor visits, and samples

● Information encoded in unstructured patient records

● Shifting towards complete genomic analysis of patients

● High Volume and Variety

16

Another Challenge (Opportunity): One size does not fit all

17

Off-shore research &

clinical trials

CROs

Not invented here

anymore

Collaborators

Local labs

Consolidated

Centralized R&D

Growing middle class

and access to

healthcare

Emerging Markets

Another Challenge (Opportunity): Distributed Research & Development

Mainframe

Centralized

Concrete

Isolated

Secretive

OLD NEW

Cloud

Distributed

Virtual

Social

Public

18

Transactional Systems, Data Silos, Discovery & Access Restrictions

Isolation

Distributed Research Models Limited Sharing and Collaboration

Collaboration

On-premise Data Centers, Expensive and Complex

Infrastructure

Patients, Assays, Tissues, Organisms, Proteins, Genes,

Variety

100,000s of samples, 100s of GB per Day per Experiment

Volume

Structured vs. Unstructured Data, How to make Sense of the Data

Complexity

Many Informatics Challenges (Opportunities) in Life Science

19

New Informatics for New Science

The pace of life science data generation and the complexity of the

generated data is outperforming existing informatics solutions

20

Collaboration

Data Analysis

&

Visualization

Scientific

Smarts

Data

Integration

Scientific Informatics Platform

E-Notebook, Signals and cloud

platform to support scientific

research

Collaboration

Scientific intelligence, modeling

& workflows

Scientific Smarts

Best in class data analytics,

visualization & workflows

Data Analysis & Visualization

Unified access to all your

relevant data sources

Data Integration

PerkinElmer Informatics: Big Data Prescription for R&D

Supporting new speed of science

21 21

Lets you access &

assemble all

of your data

Right Data

Right Time

Right Person

“If you can establish a common visual language for data, you can radically upgrade the use of that data to drive decision-making and action.”

Thomas H. Davenport Harvard Business Review blog, 2013

World-renowned author & business analytics expert

22

PKI Columbus Image Acquisition

Spotfire Analytics & Visualization

On-Premise Columbus

Signals for Screening

Servers 1 Server, 16 CPUs, 32GB

4000 Node Cluster

1 Plate 2 Days 3 Minutes

100 Plates 200 Days 30 Minutes

High Content Screening: Signals for Imaging

(Jens Hoefkens)

• Data ingestion, curation • Search, retrieval • Multi-parametric analysis • Applications (workflows)

Data Import and Aggregation

Spotfire Templates

High Content Profiler

Curve Fitting

SAR

Real-time Analytics

Alerts, Reports, Publish, Collaborate

Automated Workflow

23

Quantitative Pathology

(Trent Norris)

24

Clinical & Real World Evidence

(Jamie Powers)

Source: Adapted from McKinsey Practice Perspectives on RWD

25

Signals Perspectives (Attivio): Get a 360° View of Available Data

(Brendon Kellner)

A

Enrichment

Classify

Provision Ingest

Semi structured

Unstructured

Flat file (ad-hoc or fileshare

26

Gartner Hype Cycle Life Sciences (2016) What’s on the horizon that we need to pay attention to…

Source: Gartner (July 2016)

Key INF Focus Areas

Adjacent Areas

PerkinElmer Uniquely Positioned to Deliver Future Solutions

27

Redefining Scientific Analytics Solutions: High Content Screening

“HC Profiler simplifies and standardizes high content analysis by following a logical workflow from quality control to feature and ultimately hit selection. PerkinElmer has leveraged Spotfire’s rich data visualization capabilities and underlying R architecture to provide the necessary analytical tools for HCS, all in one convenient package."

Top Pharma

Capture & Collaboration Analytics, Insight

Ideation Detection/Data File Analysis

Intensity Texture Morphology

• Complete instrument to insight HCS solution • Delivering greater customer value

The right gene

The right compound

Many locations Hundreds of studies Millions of cells Bill ions of features

28

High Content Screening: Operetta CLS & Signals for Imaging

What?

Why?

• New mid-range high content screening (HCS) platform: successor to existing Operetta

with superior image quality and flexibility

• Used in drug screening to identify most relevant drug candidates prior to costly

preclinical and clinical phase

• Signals is a big data management, aggregation, and analysis platform supporting the

complete research and precision medicine workflow

• Advanced technology leading to superior results with complex models

• Affordable and accessible HCS: optical quality and flexibility of high-end Opera

Phenix (but lower throughput) at mid-range price

40x Air 40x Water = 4x brighter

29

by

Analytics &

IoT Instrumentation

Information

Services

Scientific

Services Compliance

• Leading Scientific

Laboratory Solutions

provider (OneSource)

• #1 in Data Visualization

Software Solutions

• Serving all of the 20 Largest

Pharma Companies

Pharma /

BioPharma

Services

Services & Informatics

>95 customer programs

across

>350 sites in over 20

countries

>500,000 MV ASSETS SERVICED

$475M+ Services revenue

“By leveraging analytics across the IoT spectrum and connecting previously disconnected data elements from the exisitng instrumentation, performance can be better monitored and new insights can

be generated” –Gartner Life Science Hype Cycle

IoT

30

Towards a Scientific Drug Discovery Informatics Platform Bringing the Pieces Together

Customer Needs

Utilizes cloud and mobile technologies

Simplifies IT environment

Integrates best in class applications

Provide cohesive

user experience

Lowers TCO

Supports distributed research

Improves data access / integration

Increases R&D productivity

Research ELN

Inventory Registration

Assay Data Management

LIMS Dev ELN

Image Data Management

SDMS CDS Predictive Modeling

EDC

Scientific Apps

Chemistry Image

Analysis Clinical Apps

Third-Party Apps

Services

Cloud

Analytics & Visualization

Se

arc

h

Da

ta

Inte

gra

tio

n

External Partners

/ Collaborators

Internal

Users

HCProfiler CDR, RBM, RWE

IoT

E L N i s C e n t r a l F u n c t i o n a l i t y

“These systems can reduce IT complexity and change the high IT cost models…can also enable rapid set-up with collaborative partners and facilitate drug discovery and

external partnering strategies for external innovation” –Gartner Life Science Hype Cycle

31

W E E M P O W E R S C I E N T I S T S T O M A K E B E T T E R D E C I S O N S

32

Turning the Corner on Eroom’s Law?

33

A parting thought….

“One of the very few silver linings about me getting sick is that Reed’s gotten

to spend a lot of time studying with some very good doctors… I think the

biggest innovations of the twenty-first century will be the intersection of biology and technology. A new era is beginning, just like the digital one when I was his age.”

-Steve Jobs

34

Driving INNOVATION to provide INSIGHTS

that make an IMPACT